Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2193]

COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity...

Dr Sumanta K. Pal - City of Hope Comprehensive Cancer Center, Duarte, USA

COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity in inoperable locally advanced/metastatic urothelial carcinoma ( Dr Sumanta K. Pal - City of Hope Comprehensive Cancer Center, Duarte, USA )

Safety follow-up of the randomized, phase 3 study DESTINY-Breast03

Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA

Safety follow-up of the randomized, phase 3 study DESTINY-Breast03 ( Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA )

Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC

Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan

Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC ( Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan )

High-dose ifosfamide standard of care for recurrent and primary refractory...

Dr Martin McCabe - University of Manchester, Manchester, England

$High-dose ifosfamide standard of care for recurrent and primary refractory ewing sarcoma ( Dr Martin McCabe - University of Manchester, Manchester, England )$

Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM: Phase 3...

Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA

Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM: Phase 3 DETERMINATION trial ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )

Single-agent PD-1 blockade as curative-intent treatment in mismatch repair...

Dr Andrea Cercek - Memorial Sloan Kettering Cancer Centre, Manhattan, New York

Single-agent PD-1 blockade as curative-intent treatment in mismatch repair-deficient locally advanced rectal cancer ( Dr Andrea Cercek - Memorial Sloan Kettering Cancer Centre, Manhattan, New York )

N-803-BCG combination shows promising results in BCG-unresponsive NMIBC

Dr Karim Chamie - UCLA School of Medicine, Los Angeles, USA

N-803-BCG combination shows promising results in BCG-unresponsive NMIBC ( Dr Karim Chamie - UCLA School of Medicine, Los Angeles, USA )

Ibrutinib improves PFS by 50% for older patients with newly diagnosed mantle...

Dr Michael Wang - MD Anderson Cancer Center, Houston, USA

Ibrutinib improves PFS by 50% for older patients with newly diagnosed mantle cell lymphoma ( Dr Michael Wang - MD Anderson Cancer Center, Houston, USA )

Circulating tumour DNA analysis can help identify the need for adjuvant therapy...

Dr Jeanne Tie - The Peter MacCallum Cancer Centre, Melbourne, Australia

Circulating tumour DNA analysis can help identify the need for adjuvant therapy in stage II colon cancer ( Dr Jeanne Tie - The Peter MacCallum Cancer Centre, Melbourne, Australia )

Circulating tumour DNA analysis can help identify the need for adjuvant therapy...

Dr Jeanne Tie - Peter MacCallum Cancer Centre, Melbourne, Australia

Circulating tumour DNA analysis can help identify the need for adjuvant therapy in stage II colon cancer ( Dr Jeanne Tie - Peter MacCallum Cancer Centre, Melbourne, Australia )

UICC announces global coalition to increase access to essential cancer...

Dr Cary Adams - Chief Executive Officer, UICC

UICC announces global coalition to increase access to essential cancer medicines in low and lower middle-income countries ( Dr Cary Adams - Chief Executive Officer, UICC )

ASCO and WHO to collaborate on quality indicators for cancer facilities

Dr André Ilbawi - Cancer Control Officer, WHO

ASCO and WHO to collaborate on quality indicators for cancer facilities ( Dr André Ilbawi - Cancer Control Officer, WHO )

More from ecancer